Roles of immune microenvironment heterogeneity in therapy-associated biomarkers in lung cancer

Area of Science:

• Oncology
• Immunology

Background:

• Lung cancer progression involves complex interactions between cancer cell mutations and the tumor microenvironment.
• Current targeted therapies show modest efficacy due to lung cancer's heterogeneous mutations.

Purpose of the Study:

• To review the diversity of immune cells, cytokines, and genes within the tumor microenvironment.
• To explore the potential of targeted mono and combined therapies for lung cancer.
• To enhance understanding of lung cancer heterogeneity and drug resistance mechanisms.

Main Methods:

• Literature review of studies on lung cancer, tumor microenvironment, and immune components.
• Analysis of immune cell, cytokine, and gene diversity in the tumor microenvironment.
• Evaluation of targeted therapy strategies, including monotherapy and combination approaches.

Main Results:

• The tumor immune microenvironment significantly influences lung cancer outcomes through a balance of suppressive and cytotoxic responses.
• Immune microenvironment heterogeneity is a critical factor contributing to overall lung cancer heterogeneity.
• Diversity in immune cells, cytokines, and genes within the tumor microenvironment presents therapeutic targets.

Conclusions:

• Targeting the diverse components of the tumor immune microenvironment offers potential strategies to overcome lung cancer heterogeneity and drug resistance.
• A deeper understanding of immune cell dynamics and targeted therapies is crucial for improving patient outcomes in lung cancer.